pandemic

European responses to the corona crisis – Part 13

During the Coronavirus crises, the European Science-Media Hub is collecting and publishing a regular update of the most relevant releases provided by EU institutions and other European and global actors. 🆕 Last Update : 27 Feb 2021

Coronavirus Covid-19 treatment illustration banner

Passive immunisation for COVID-19

There is currently no specific treatment for SARS-CoV-2. However, a number of treatments have been explored in patients with life-threatening COVID-19 (such as antimalarial drugs, antivirals, immunomodulatory agents, and glucocorticoids) with varying results. Convalescent plasma collected from recovered COVID-19 patients, containing antibodies against SARS-CoV-2, could potentially be an effective therapeutic tool. In addition, preclinical studies ...

Light Bulbs Concept

An expert’s opinion: An interview with Ludo Waltman on the surge in COVID-19 research papers

We speak with Ludo Waltman, Professor of Quantitative Science Studies and Deputy Director of the Centre for Science and Technology Studies (CWTS) at Leiden University, on how the COVID-19 pandemic is changing the way we assess the quality of scientific literature. What are you working on at the moment? I am looking at how many ...

Light Bulbs Concept

An expert’s opinion: An interview with Adam Marcus on scientific publishing in times of COVID-19

Adam Marcus, Co-founder of Retraction Watch and managing editor of Gastroenterology & Endoscopy News, highlights the need to be vigilant about the quality of COVID-19 research papers and encourages publishers to publish fewer but better-quality papers. How many COVID-19 papers have been retracted so far this year? Our latest count is 37 retractions and three ...

Light Bulbs Concept

Covid-19: What are the consequences of the unprecedented rush for knowledge?

The surge in COVID-19 research papers has put the spotlight on the peer review process and is changing the way we assess the quality of scientific literature.

Coronavirus Covid-19 treatment illustration banner

Tocilizumab : a treatment alternative in COVID-19 pneumonia

Patients with severe COVID-19 pneumonia often need to be mechanically intubated and have an increased mortality risk. Tocilizumab, a drug used against the cytokine storm underlying this clinical condition, has shown positive effects in clinical trials.

Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Prof Cristina Mussini about covid-19 treatment

Interview with Professor Cristina Mussini, Head of the Department of Infectious Diseases and Tropical Medicine at the University of Modena and Reggio Emilia in Italy and member of the European AIDS Clinical Society. She has been actively involved in various recent studies on the clinical use of tocilizumab in patients with COVID-19 pneumonia. First a ...

Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Dr Andrew Ip about covid-19 treatment

Interview with Dr Andrew Ip, a specialist in hematology/oncology at the John Theurer Cancer Center at Hackensack University Medical Center, USA, who has been involved in research on tocilizumab use in COVID-19 patients. Why did you choose tocilizumab to treat patients with COVID-19 pneumonia? Tocilizumab is a monoclonal antibody that inhibits the interleukin-6 (IL-6) receptor. ...

Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Dr Juan Victor San-Martin Lopez about covid-19 treatment

Interview with Dr Juan Victor San-Martín López, a physician specialising in infectious diseases and a member of the task force coordinating responses to the leishmaniasis outbreak in 2011 and to COVID-19 at the Hospital Universitario de Fuenlabrada, Spain. He reports on his experience with tocilizumab use in COVID-19 patients. What is the so-called cytokine storm? ...

Coronavirus Covid-19 treatment illustration banner

The key role of antivirals in COVID-19 treatment

A few weeks after the SARS-CoV-2 was identified by Chinese researchers as the cause of ‘COVID-19’, an antiviral called remdesivir, originally used during the 2014 Ebola outbreak, came into play as the first available option to treat patients with coronavirus disease 2019 (COVID-19). Even if the approval process for remdesivir caused some controversy, experts consider the combined use of antivirals and other drugs a promising solution for treatment of Covid-19.